N-carbacycle monosubstituted indolocarbazoles as protein kinase inhibitors

US7262215B2 · kind B2 · utility

Assignee

• NAD AG · DE

Inventors

• Heidi Sahagun-Krause · Birkenfeld, DE
• Olivier Thillaye Du Boullay · Markt Indersdorf, DE
• Valerie Thillaye Du Boullay · Markt Indersdorf, DE
• Laura Casiraghi · Birkenfeld, DE
• Hans Klafki · Birkenfeld, DE
• Pierfausto Seneci · Milano, IT
• Tobias Braxmeier · Gaggenau, DE
• Silvia Müller · Birkenfeld, DE
• Wolfgang Fr{hacek over (o)}hner · Birkenfeld, DE
• Barbara Monse · Weichs, DE
• Sandra Gordon · Mariefred, SE
• Hanno Roder · Ratingen, DE

Key dates

• Filing date: Dec 4, 2002
• Grant date: Aug 28, 2007
• Expiry date: Dec 4, 2022

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This invention relates to N-carbacycle monosubstituted indolocarbazole compounds. Furthermore, this invention relates to medicaments comprising N-carbacycle monosubstituted indolocarbazoles compounds and the use of such compounds for treating non-insulin dependent diabetes mellitus, acute stroke and other neurotraumatic injuries, for treating diabetes mellitus, as a chemotherapeutic for the treatment of various malignant diseases, for treating diseases caused by malfunctioning of specific signaling pathways, and for treating neurodegenerative diseases such as for example Alzheimer's disease.